Akero Therapeutics, Inc.
AKRODelisted Dec 9, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001744659
Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 267 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:09 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 27, 2025 | Feb 29, 2024 | Mar 17, 2023 | Feb 25, 2022 | Mar 16, 2021 |
| Research and development | $247.5M | $141.8M | $85.3M | $81.8M | $64.9M |
| Selling, general and administrative | $37.9M | $31.1M | $29.9M | $19.1M | $15.2M |
| Operating income | -$285.4M | -$172.9M | -$115.2M | -$100.9M | -$80.2M |
| Interest expense | $4.67M | $3.10M | $739.0K | – | – |
| Net income | -$252.1M | -$151.8M | -$112.0M | -$100.8M | -$79.2M |
| EPS, basic | $-3.75 | $-2.89 | $-2.87 | – | – |
| EPS, diluted | $-3.75 | $-2.89 | $-2.87 | $-2.89 | – |
| Weighted shares, basic | 67.1M | 52.6M | 39.0M | – | – |
| Weighted shares, diluted | 67.1M | 52.6M | 39.0M | 34.8M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 27, 2025 | Feb 29, 2024 | Mar 17, 2023 | Feb 25, 2022 | Mar 16, 2021 |
| Cash and equivalents | $340.2M | $234.2M | $249.8M | $150.5M | $187.2M |
| Short-term investments | $402.8M | $315.8M | $101.7M | $37.8M | $81.1M |
| Total current assets | $770.4M | $560.0M | $355.2M | $193.6M | $271.3M |
| Property, plant and equipment | – | $18.0K | $47.0K | $90.0K | $131.0K |
| Total assets | $825.9M | $580.3M | $356.6M | $195.5M | $273.3M |
| Accounts payable | $9.03M | $7.04M | $7.97M | $6.71M | $3.43M |
| Total current liabilities | $39.8M | $19.1M | $19.1M | $25.1M | $13.1M |
| Total liabilities | $75.8M | $45.0M | $30.0M | $26.4M | $14.6M |
| Shareholders' equity | $750.1M | $535.3M | $326.6M | $169.1M | $258.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 27, 2025 | Feb 29, 2024 | Mar 17, 2023 | Feb 25, 2022 | Mar 16, 2021 |
| Operating cash flow | -$230.1M | -$145.4M | -$92.5M | -$79.7M | -$70.8M |
| Capital expenditures | – | – | – | – | $148.0K |
| Free cash flow | – | – | – | – | -$71.0M |
| Stock-based compensation | $29.7M | $21.5M | $23.2M | $10.1M | $6.02M |
| Investing cash flow | -$109.7M | -$223.6M | -$63.8M | $42.3M | -$9.76M |
| Financing cash flow | $445.8M | $353.3M | $255.6M | $602.0K | $203.1M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2025 | 82.3M | +17.9% | SEC |
| Jul 31, 2025 | 80.0M | +15.2% | SEC |
| May 1, 2025 | 79.7M | +15.3% | SEC |
| Feb 14, 2025 | 79.6M | +41.4% | SEC |
| Oct 31, 2024 | 69.8M | +25.3% | SEC |
| Aug 2, 2024 | 69.4M | +24.9% | SEC |
| May 3, 2024 | 69.2M | +38.1% | SEC |
| Feb 23, 2024 | 56.3M | +19.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.